Literature DB >> 7490333

CD34 immunoperoxidase staining for the diagnosis of myelodysplastic syndromes and chronic myeloid leukaemia.

A Orazi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490333      PMCID: PMC502888          DOI: 10.1136/jcp.48.9.884-a

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  5 in total

1.  Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.

Authors:  D Soligo; D Delia; A Oriani; G Cattoretti; A Orazi; V Bertolli; N Quirici; G L Deliliers
Journal:  Leukemia       Date:  1991-12       Impact factor: 11.528

2.  QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens.

Authors:  H P Horny; M Wehrmann; H U Schlicker; A Eichstaedt; M R Clemens; E Kaiserling
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

3.  Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment.

Authors:  A Orazi; G Cattoretti; D Soligo; R Luksch; G Lambertenghi-Deliliers
Journal:  Leukemia       Date:  1993-06       Impact factor: 11.528

4.  CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia.

Authors:  A Orazi; R S Neiman; H Cualing; N A Heerema; K John
Journal:  Am J Clin Pathol       Date:  1994-04       Impact factor: 2.493

5.  CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes.

Authors:  D A Soligo; A Oriani; C Annaloro; A Cortelezzi; R Calori; E Pozzoli; D Nosella; A Orazi; G L Deliliers
Journal:  Am J Hematol       Date:  1994-05       Impact factor: 10.047

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.